{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:49:56Z","timestamp":1784332196571,"version":"3.55.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1097\/mph.0000000000000277","type":"journal-article","created":{"date-parts":[[2014,11,6]],"date-time":"2014-11-06T05:25:13Z","timestamp":1415251513000},"page":"e111-e113","source":"Crossref","is-referenced-by-count":4,"title":["Nonhematologic Toxicity of Imatinib Mesylate in Pediatric Patients With Chronic Myelogenous Leukemia"],"prefix":"10.1097","volume":"37","author":[{"given":"Kenneth M.","family":"Heym","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Gressett Ussery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Trinkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey M.","family":"Philpot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-22-20210209","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1002\/cncr.11316","article-title":". Trends in leukemia incidence and survival in the United States (1973-1998).","volume":"97","author":"Xie","year":"2003","journal-title":"Cancer"},{"key":"R2-22-20210209","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.","volume":"105","author":"Druker","year":"2000","journal-title":"J Clin Invest"},{"key":"R3-22-20210209","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":". Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"R4-22-20210209","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","article-title":". Practical management of patients with chronic myeloid leukemia receiving imatinib.","volume":"21","author":"Deininger","year":"2003","journal-title":"J Clin Oncol"},{"key":"R5-22-20210209","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1056\/NEJM200202283460919","article-title":"Adverse events after imatinib mesylate therapy.","volume":"346","author":"Burton","year":"2002","journal-title":"N Engl J Med"},{"key":"R6-22-20210209","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":". Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"R7-22-20210209","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":". Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"R9-22-20210209","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1002\/cncr.11895","article-title":". Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.","volume":"98","author":"Kolb","year":"2003","journal-title":"Cancer"},{"key":"R10-22-20210209","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","article-title":". Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.","volume":"21","author":"Hahn","year":"2003","journal-title":"J Clin Oncol"},{"key":"R11-22-20210209","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":". Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"R12-22-20210209","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":". Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"R13-22-20210209","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood-2003-09-3032","article-title":". Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Childrens Oncology Group phase 1 study.","volume":"104","author":"Champagne","year":"2004","journal-title":"Blood"},{"key":"R14-22-20210209","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":". Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.","volume":"29","author":"Millot","year":"2011","journal-title":"J Clin Oncol"},{"key":"R15-22-20210209","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3324\/haematol.2009.015180","article-title":". Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia.","volume":"95","author":"Belgaumi","year":"2010","journal-title":"Haematologica"},{"key":"R16-22-20210209","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.beha.2009.06.001","article-title":"Management of drug toxicities in chronic myeloid leukaemia.","volume":"22","author":"Mauro","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"R17-22-20210209","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3324\/haematol.2009.008359","article-title":". Longitudinal growth retardation in a prepubertal girl with chronic myeloid leukemia on long-term treatment with imatinib.","volume":"94","author":"Schmid","year":"2009","journal-title":"Haematologica"},{"key":"R18-22-20210209","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12185-008-0251-8","article-title":"Growth deceleration in a girl treated with imatinib.","volume":"89","author":"Kimoto","year":"2009","journal-title":"Int J Hematol"},{"key":"R19-22-20210209","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(08)61023-5","article-title":". Low bone density and decreased inhibin-BFSH ratio in a boy treated with imatinib during puberty.","volume":"372","author":"Mariani","year":"2008","journal-title":"Lancet"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000000277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:46:10Z","timestamp":1620963970000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201503000-00022"}},"subtitle":["A Predominance of Musculoskeletal Pain"],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000000277","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}